MORE DETAILS ON OUR COVID MEASURES - CLICK THIS BAR
Myxofibrosarcoma is an aggressive form of soft tissue sarcoma. Myxofibrosarcoma’s are frequently found in connective tissue (fatty tissue around muscles and beneath the skin) and have a highly infiltrative appearance.
Myxofibrosarcoma most often develops in adults between the age of 50 and 80 years. It commonly occurs in the extremities and especially the lower legs.
Myxofibrosarcoma development is still poorly understood. It results due to DNA mutations in connective tissue cells leading to uncontrolled growth and formation of mutated cells, resulting in tumour formation.
The symptoms for Myxofibrosarcoma include:
Doctors use a variety of tests to confirm a myxofibrosarcoma diagnosis. These tests include the following:
The most common treatment for myxofibrosarcoma is surgical removal of the tumour. This can be a challenging process depending on where the tumour is located. The aim of surgery is to remove the tumour with a margin of normal surrounding tissue if possible. This improves the chance of cure and reduces the risk of the tumour re-occurring. Myxofibrosarcoma’s are known to be highly infiltrative and a wide margin of normal tissue needs to be removed to ensure all the tumour is removed.
Sometimes, radiation therapy or chemotherapy is given before surgery to help shrink the tumour and improve the results (compared with surgery alone).
The use of radiotherapy for these tumours is common. Radiotherapy (either before or after surgery) is useful in the management of myxofibrosarcomas. It has been shown to reduce the chance of the tumour re-occurring locally after surgical resection.
Chemotherapy is reserved for select cases, studies have shown benefit from chemotherapy following surgical resection for larger myxofibrosarcomas.
Contact Details
Suite 1A, Level 7, Prince of Wales Private Hospital, Randwick, 2031
(02) 8073 9462